Skip Navigation LinksHome > January 2014 - Volume 93 - Issue 1 > Inflammatory Arthritis in Patients With Myelodysplastic Synd...
Text sizing:
doi: 10.1097/MD.0000000000000011
Original Study

Inflammatory Arthritis in Patients With Myelodysplastic Syndromes: A Multicenter Retrospective Study and Literature Review of 68 Cases

Mekinian, Arsène MD; Braun, Thorsten MD; Decaux, Olivier MD; Falgarone, Géraldine PhD; Toussirot, Eric PhD; Raffray, Loic MD; Omouri, Mohamed MD; Gombert, Bruno MD; De Wazieres, Benoit PhD; Buchdaul, Anne-Laure MD; Ziza, Jean-Marc PhD; Launay, David PhD; Denis, Guillaume MD; Madaule, Serge MD; Rose, Christian MD; Grignano, Eric MD; Fenaux, Pierre PhD; Fain, Olivier MD; on behalf of the Club Rhumatismes et Inflammation (CRI), Groupe Francophone des Myélodysplasies (GFM), and Société Nationale Française de Médecine Interne (SNFMI)

Supplemental Author Material
Collapse Box


Abstract: We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study.

Twenty-two patients with MDS (median age, 77.5 yr [interquartile range, 69–81]; 10 women) were included. Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). At diagnosis, the median disease activity score 28 based on C-reactive protein (DAS28-CRP) was 4.5 [2–6.5]. Two patients had anti-citrullinated protein antibodies (ACPAs), and 1 had radiologic erosions. The median time between the diagnoses of arthritis and MDS was 10 months [6–42], with a median articular symptom duration of 3 months [2–8]. The diagnosis of both diseases was concomitant in 6 cases (27%); arthritis preceded MDS in 12 cases (55%), and occurred after MDS in 4 (18%). While the number of swollen and tender joints significantly decreased during follow-up, as did the median DAS28-CRP (from 4.3 [3.8–4.6] at baseline to 2.9 [1.75–3.3]; p < 0.05), CRP remained elevated (CRP >20 mg/L) in 8 patients (42%). Nevertheless, radiographic progression and new ACPA positivity were not observed during a median follow-up of 29 months [9–76]. While most of the patients were treated with steroids (n = 16) for arthritis, additional treatment was administered in only 4 patients (hydroxychloroquine, n = 2; sulfasalazine [Salazopyrin] and etanercept, n = 1, respectively). Eleven patients died during follow-up from acute myeloid leukemia (n = 5); infections (n = 3); or cerebral bleeding, cardiorespiratory failure, or undetermined cause (n = 1, respectively).

Inflammatory arthritis associated with MDS can have various presentations and is often seronegative and nonerosive. Steroids alone are the most common treatment in MDS-associated arthritis, but that treatment is insufficient to control arthritis. Steroid-sparing strategies need to be identified.

© 2014 by Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics